A RANDOMIZED, MASKED, CONTROLLED STUDY OF OMEGA-3 POLYUNSATURATED FATTY ACID

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 欧米茄-3-多不饱和脂肪酸已被证明同时抑制肝脏脂肪合成，同时上调脂肪酸氧化。大量使用omega-3多不饱和脂肪酸(PUFA)饮食补充的临床研究已导致极低密度脂蛋白胆固醇和血清甘油三酯降低。然而，评估omega-3-PUFA对非酒精性脂肪性肝病患者肝脏脂肪变性的影响的详细临床研究尚未进行。这项建议是进行一项平行的安慰剂对照研究，以确定饮食补充omega-3多不饱和脂肪酸对非酒精性脂肪性肝病患者的影响。这项研究的主要结果衡量标准将是磁共振波谱确定的肝内脂肪含量的减少。还将分析omega-3-PUFA对肝脏坏死性炎症、血压、血清炎症标志物、胰岛素敏感性和脂肪酸氧化的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Omega-3-polyunsaturated fatty acids have been shown to simultaneously suppress hepatic lipid synthesis while upregulating fatty acid oxidation. Numerous clinical studies using dietary supplementation with omega-3 polyunsaturated fatty acids (PUFA) have resulted in decreased VLDL cholesterol and serum trigylcerides. However a detailed clinical study evaluating the effects of omega-3-PUFA on hepatic steatosis in patients with non-alcoholic fatty liver disease has not been performed. This proposal is to perform a parallel, placebo-controlled study to determine the effects of dietary supplementation with omega-3 PUFA in patients with non-alcoholic fatty liver disease. The primary outcome measure of this study will be the reduction of intrahepatic fat content as determined by magnetic resonance spectroscopy. The effects of omega-3-PUFA on hepatic necroinflammation, blood pressure, serum markers of inflammation, insulin sensitivity and fatty acid oxidation will also be analyzed.